Racial Differences in Clinical Use of Cinacalcet in a Large Population of Hemodialysis Patients
Open Access
- 30 July 2013
- journal article
- research article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 38 (2) , 104-114
Abstract
Background/Aims: African-Americans with end-stage renal disease receiving dialysis have more severe secondary hyperparathyroidism than Whites. We aimed to assess racial differences in clinical use of cinacalcet. Methods: This retrospective cohort study used data from DaVita, Inc., for 45,589 prevalent hemodialysis patients, August 2004, linked to Centers for Medicare & Medicaid Services data, with follow-up through July 2007. Patients with Medicare as primary payer, intravenous vitamin D use, or weighted mean parathyroid hormone (PTH) level >150 pg/ml at baseline (August 1-October 31, 2004) were included. Cox proportional hazard modeling was used to evaluate race and other demographic and clinical characteristics as predictors of cinacalcet initiation, titration, and discontinuation. Results: Of 16,897 included patients, 7,674 (45.4%) were African-American and 9,223 (54.6%) were white; 53.2% of cinacalcet users were African-American. Cinacalcet was prescribed for 47.7% of African-Americans and 34.5% of Whites, and for a greater percentage of African-Americans at higher doses at each PTH strata. After covariate adjustment, African-Americans were more likely than Whites to receive cinacalcet prescriptions (hazard ratio 1.17, p < 0.001). The direction and magnitude of this effect appeared to vary by age, baseline PTH, and calcium, and by elemental calcium use. African-Americans were less likely than Whites to have prescriptions discontinued and slightly more likely to undergo uptitration (hazard ratio 1.09, 95% confidence interval 0.995-1.188), but this relationship lacked statistical significance. Conclusion: Cinacalcet is prescribed more commonly and at higher initial doses for African-Americans than for Whites to manage secondary hyperparathyroidism.Keywords
This publication has 18 references indexed in Scilit:
- Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patientsJournal of Bone and Mineral Research, 2010
- Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patientsKidney International, 2010
- Possible Effects of the New Medicare Reimbursement Policy on African Americans with ESRDJournal of the American Society of Nephrology, 2009
- Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006Clinical Journal of the American Society of Nephrology, 2009
- Effects of Monthly Dose and Regular Dosing of Intravenous Active Vitamin D Use on Mortality Among Patients Undergoing HemodialysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns StudyNephrology Dialysis Transplantation, 2008
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- Impact of Activated Vitamin D and Race on Survival among Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- Prevalence of Cardiovascular Risk Factors and the Serum Levels of 25-Hydroxyvitamin D in the United StatesArchives of internal medicine (1960), 2007
- Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal diseaseKidney International, 1998